This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Linde, H.-J.
Right arrow Articles by Lehn, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Linde, H.-J.
Right arrow Articles by Lehn, N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2001, p. 1553-1557, Vol. 45, No. 5
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.5.1553-1557.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Activities of Six Quinolones and Mechanisms of Resistance in Staphylococcus aureus and Coagulase-Negative Staphylococci

Hans-Jörg Linde,* Mario Schmidt, Emmi Fuchs, Udo Reischl, Hans-Helmut Niller, and Norbert Lehn

Institute for Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany

Received 31 October 2000/Returned for modification 18 December 2000/Accepted 30 January 2001

Of 94 clinical isolates of Staphylococcus aureus (n = 51) and coagulase-negative staphylococci (CNS) (n = 43), mutations in the quinolone resistance-determining region of topoisomerases GrlA, GrlB, GyrA, and GyrB together with MICs of six quinolones were analyzed. Amino acid substitutions at identical residues (GrlA residues 80 and 84; GyrA residues 84 and 88) were found in S. aureus and CNS. Active efflux, as suggested by blocking by reserpine, contributed substantially to the resistance phenotype in some strains. Among ciprofloxacin, clinafloxacin, levofloxacin, nalidixic acid, trovafloxacin, and sparfloxacin, a 0.5-µg/ml concentration of sparfloxacin discriminated best between strains with two or three mutations and those with no mutations.

* Corresponding author. Mailing address: Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg, Franz-Josef-Strauss-Allee 11, D-93049 Regensburg, Germany. Phone: 49-941- 944-6461. Fax: 49-941-944-6402. E-mail: hans-joerg.linde{at}klinik.uni-regensburg.de.

Antimicrobial Agents and Chemotherapy, May 2001, p. 1553-1557, Vol. 45, No. 5
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.5.1553-1557.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Bogdanovich, T., Esel, D., Kelly, L. M., Bozdogan, B., Credito, K., Lin, G., Smith, K., Ednie, L. M., Hoellman, D. B., Appelbaum, P. C. (2005). Antistaphylococcal Activity of DX-619, a New Des-F(6)-Quinolone, Compared to Those of Other Agents. Antimicrob. Agents Chemother. 49: 3325-3333 [Abstract] [Full Text]  
  • Lin, G., Credito, K., Ednie, L. M., Appelbaum, P. C. (2005). Antistaphylococcal Activity of Dalbavancin, an Experimental Glycopeptide. Antimicrob. Agents Chemother. 49: 770-772 [Abstract] [Full Text]  
  • Hoellman, D. B., Pankuch, G. A., Appelbaum, P. C. (2004). Antistaphylococcal Activity of CB-181963 (CAB-175), an Experimental Parenteral Cephalosporin. Antimicrob. Agents Chemother. 48: 4037-4039 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»